About this company
We're addressing the unmet medical need in autism therapeutics, impacting over 1% of the population with limited treatment options. Our team, based at the University of Basel, comprises experts in the field, including Professor Peter Scheiffele in neuroscience, autism researcher Dr. Özgür Genç, and medicinal chemist Dr. Guido Koch. The discovery of the selective mRNA translation pathway as a converging point in autism spectrum disorders offers an innovative opportunity for autism therapeutics. Our focus is on developing brain-penetrant, selective MNK inhibitors to regulate dysregulated RNA translational homeostasis. This innovation directly applies to autism subtypes characterized by pathology in the RNA translational pathway, such as Fragile X, Phelan McDermid, and Tuberous Sclerosis.